Distribution of the Recombinant Coagulation Factor ¹²⁵I-rFVIIa in Rats

Summary

Recombinant human factor VIIa (rFVIIa; NovoSeven®) is a two-chain activated clotting factor that is used in the treatment of haemophilia. The distribution of radioactivity in male and pregnant and non-pregnant female rats has been examined by whole-body autoradiography (WBA) after single intravenous doses of ¹²⁵I-radiolabelled rFVIIa at a dosage level of ca. 0.1 mg/kg.

Concentrations of radioactivity were highest in the blood and the highly perfused major thoracic and visceral organs and gonads. This distribution of radioactivity was generally similar in pregnant and non-pregnant females, and although radioactivity was concentrated in the foetal thyroid, it was present in other foetal tissues only at trace levels. Radioactivity in thyroid, urinary bladder and gastrointestinal tract of all rats was apparently associated with detached ¹²⁵I-iodide. At early sacrifice times (up to 2 h), radioactivity was present in the bone marrow, but at later times (6-24 h) it was apparently associated with the mineralised bone structures.

The quantitative distribution of total and trichloroacetic acid precipitable radioactivity in the tissues of rats also was studied after single intravenous doses of ¹²⁵I-rFVIIa and ¹²⁵I-rFVII, the non-activated single chain precursor of FVIIa, which is normally present in the circulation. These studies confirmed the WBA findings and showed that the tissue distribution of ¹²⁵I-rFVII and ¹²⁵I-rFVIIa was similar, indicating that the distribution of rFVIIa during therapy would be similar to that produced from endogenous FVII as a physiological response to vascular injury.

• References

• 1 Hedner U, Kiesel W. Use of human factor VIIa in the treatment of two haemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71: 1836-1841
• 2 Hedner U, Ljungberg J, Lund-Hansen T. Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model. Blood Coag Fibrinol 1990; 1: 145-151
• 3 Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. Effect of recombinant factor VIIa on the haemostatic defect in dogs with haemophilia A, haemophilia B and von Willebrand disease. Proc Natl Acad Sci 1989; 86: 1382-1386
• 4 Ullberg S, Larsson B. Whole-body autoradiography. In: Progress in Drug Metabolism. Bridges JW, Chasseaud LF. (eds) John Wiley & Sons Ltd.; London: 1981. Vol 6 249-289
• 5 Thomsen MK, Wildgoose P, Nilsson P, Hedner U. Importance of the Gla-domain and relevance to factor IX, another vitamin K-dependent clotting factor. Pharmacol Toxicol. (in press)
• 6 Deykin D, Chun R, Lopez A, Silversmity P. The role of the liver in serum induced hypercoagulability. J Clin Invest 1966; 45: 256-263
• 7 Seligsohn U, Kasper CK, Østerud B, Rapaport SI. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 828-837
• 8 Østerud B, Miller-Anderson M, Abilgaard V, Pryz H. The effect of anti-thrombin III on the activity of the coagulation factors VII, IX and X. Thromb Haemostas 1976; 35: 295-304
• 9 Thomsen MK, Diness V, Nilsson P, Rasmussen SN, Taylor T, Hedner U. A comparison of bio-, immuno- and isotope assays. Pharmacokinetics of recombinant factor VIIa in the rat. Thromb Haemostas 1993; 70: 458-464